Claris Lifesciences

Sector: Pharma & Healthcare (IV Fluid & Pharmaceutical Bottle Plant)  |  HQ: India  |  Founded: Not separately disclosed  |  Employees: Not separately disclosed

Listed as: Privately held  | 

Company overview

Claris Lifesciences operates in the pharma & healthcare segment of the Indian market, with a presence noted in the iv fluid & pharmaceutical bottle plant category. The company is among the recognised participants in this segment alongside other Indian and multinational players. Operations follow the standard Companies Act 2013 disclosure framework where Claris Lifesciences is incorporated as a private or public limited company under Indian law, with statutory audit, GST registration under the CGST Act 2017, and applicable sectoral compliance under FSSAI, BIS, MoEF, or sectoral regulators as relevant to the activity. The competitive set in iv fluid & pharmaceutical bottle plant includes pan-India brands, regional players, and multinational subsidiaries operating in India through wholly-owned or joint-venture structures.

Recent developments

2015-2019

Claris Lifesciences underwent significant corporate restructuring from 2015 to 2016. In May 2015, Cadila Healthcare announced plans to acquire Claris for Rs 3,400 crore [1]. This was followed by the December 2016 sale of Claris's injectables business to Baxter for Rs 4,237 crore [2,5], representing a major strategic pivot and the company's largest transaction during this period. The injectables divestiture effectively repositioned Claris away from sterile injectable manufacturing.

Earlier, in December 2012, Claris entered a joint venture with Japanese partners Otsuka Pharma and Mitsui for the Indian market, valued at approximately Rs 1,050 crore [7,9]. Otsuka subsequently increased its stake in Claris for $20 million in May 2017 [8], indicating continued Japanese interest in the company's domestic operations. The company faced regulatory headwinds with a USFDA warning letter issued to Claris Injectables in July 2018 [10], highlighting compliance challenges in its manufacturing operations.

Sources (7)

1. Cadila Healthcare to acquire Claris Lifesciences for Rs 3,400 crore - The Economic Times · The Economic Times · Thu, 21 May 2015
2. Claris Lifesciences sells injectables business to Baxter for Rs 4,237 cr - Business Standard · Business Standard · Fri, 16 Dec 2016
3. Baxter buys Claris arm for Rs 4.2k cr - The Times of India · The Times of India · Fri, 16 Dec 2016
4. Claris in `1,050 crore deal with OPF, Mitsui - Mint · Mint · Sat, 08 Dec 2012
5. Claris sells stake to Otsuka for $20 m - BioSpectrum India · BioSpectrum India · Wed, 10 May 2017
6. Claris Lifesciences inks JV with Japanese drug maker Otsuka Pharma & Mitsui for Indian market - The Economic Times · The Economic Times · Fri, 07 Dec 2012
7. USFDA issues warning letter to Claris Injectables - The Times of India · The Times of India · Tue, 17 Jul 2018

Financial performance and recent trajectory

Disclosed revenue (FY25): Not separately disclosed in segment-wise FY 2024-25 reporting.

Competitive position

Claris Lifesciences occupies a position in the iv fluid & pharmaceutical bottle plant category alongside other listed and unlisted Indian players. Competitive intensity in the segment is shaped by raw material cost cycles, distribution depth, branded versus unbranded share, and the regulatory framework governing manufacturing, FSSAI labelling (for food), BIS standards (for engineering goods), or sectoral norms. The principal competitive moats in this category are typically scale, distribution reach, brand trust, and integrated procurement. KAMRIT's project report on iv fluid & pharmaceutical bottle plant benchmarks new entrant economics against the listed peer cost structure including capex per tonne (or per unit of output), working capital intensity, gross margin band, and the EBITDA delta between organised and unorganised participants.

Key risks

Input cost volatility in the iv fluid & pharmaceutical bottle plant value chain Competitive intensity from larger Indian groups and multinational subsidiaries Regulatory tightening under FSSAI, BIS, environmental norms, or labour codes

Outlook

Claris Lifesciences is a participant in the Indian iv fluid & pharmaceutical bottle plant category, which forms part of the broader Pharma & Healthcare space. The Indian iv fluid & pharmaceutical bottle plant market continues to evolve with rising organised share, premiumisation, distribution expansion, and a regulatory architecture covering the Companies Act 2013, the Income Tax Act 1961, the CGST Act 2017, the Legal Metrology Act 2009, and sectoral statutes including the Food Safety and Standards Act 2006 (for food and beverage subsegments), the Drugs and Cosmetics Act 1940 (for pharmaceutical or healthcare adjacencies), the Environment Protection Act 1986 (for emissions and effluents), and labour codes consolidated under the four 2020 labour codes. In KAMRIT's project report framework for this category, the competitive set typically includes pan-India branded leaders, multinational subsidiaries, mid-sized regional players, and a long tail of MSME participants. The structural attractiveness of the category for new entrants is a function of (a) market growth rate, (b) the share that remains with unorganised or fragmented operators, (c) the cost of regulatory compliance, and (d) the capex intensity of plant and machinery. The KAMRIT bankable DPR for this category structures a new entrant's economics against this competitive landscape. For Claris Lifesciences specifically, public-domain disclosures provide a baseline view of operations, but segment-wise revenue, EBITDA, capacity utilisation, and forward capex plans are not separately broken out in many cases. Where the company is part of a listed group, the SEBI LODR and the Companies Act 2013 governance framework apply, with statutory audit conducted under SA 700 and CARO 2020 reporting. Where the company is unlisted, the Companies Act 2013 framework continues to govern with reduced public disclosure. The risk and opportunity outlook for Claris Lifesciences mirrors the broader iv fluid & pharmaceutical bottle plant category dynamics. Demand-side drivers include rising household consumption, urbanisation, organised retail expansion, and policy support including PLI schemes (where applicable to the segment). Supply-side risks include input cost volatility, regulatory tightening, environmental compliance escalation, and competitive intensity from larger groups or imports. Management quality, balance sheet strength, distribution depth, and the capex execution track record are the differentiators within the peer set. KAMRIT's research desk maintains a baseline reference for Claris Lifesciences as a peer benchmark within the iv fluid & pharmaceutical bottle plant category. For investors, lenders, or new entrant promoters seeking a fuller assessment of Claris Lifesciences, KAMRIT's deep-dive company profile engagement covers financial trajectory, capacity and capex, distribution and customer concentration, regulatory exposure, and the competitive position with named peers.

KAMRIT point of view

Building or competing with Claris?

KAMRIT advises promoters, family offices, and global enterprises evaluating greenfield entry into the pharma & healthcare (iv fluid & pharmaceutical bottle plant) sector. Our Bankable DPR with Cost Model and ROI benchmarks your project economics against the listed-company cost structure of Claris and peers. The Execution Partnership tier covers everything from incorporation through commissioning. A 20-minute scoping call with our partners is free.

View all 1 related project report → Book a scoping call

Related KAMRIT project reports

These reports use Claris Lifesciences in benchmarking and competitive analysis sections.

Disclaimer: This profile is compiled by KAMRIT Financial Services LLP for educational and benchmarking purposes only. It is not investment advice, a recommendation to buy or sell securities, or a solicitation. Stock data is provided by Yahoo Finance and may be delayed by up to 20 minutes. Company financial commentary draws on publicly available filings, exchange disclosures, and KAMRIT industry research. Readers should consult a SEBI-registered investment adviser before making investment decisions. KAMRIT is a financial services and compliance firm, not a SEBI-registered investment adviser.